Abstract
BackgroundRecruitment of individuals with rare diseases for studies of real-world patient-reported outcomes is limited by small base populations. Myeloproliferative neoplasms (MPNs) are a group of rare, chronic, hematologic malignancies. In this study, recruitment strategies and geographic representativeness from the Living with MPNs survey are reported.MethodsThe Living with MPNs online cross-sectional survey was conducted between April and November 2016. Individuals 18 to 70 years of age living in the United States and diagnosed with an MPN were eligible to participate. Recruitment approaches included direct contact via emails and postcards; posts on MPN-focused social media and patient advocacy websites; postcard mailings to doctors’ offices; and advertisements on medical websites, Google, and Facebook. Geographic representativeness was assessed based on the number of survey respondents living in each state or the District of Columbia and by the number of survey respondents per 10 million residents.ResultsA total of 904 respondents with MPNs completed the survey. The recruitment method yielding the greatest number of respondents was advertisements on MPN-focused social media (47.6% of respondents), followed by emails (35.1%) and postcards (13.9%) sent through MPN advocacy groups. Home state information was provided by 775 respondents from 46 states (range of respondents per state, 1–89). The number of respondents per 10 million residents in the 46 states with respondents ranged from 12.1 to 52.7.ConclusionsRecruitment using social media and communications through patient groups and advocacy organizations are effective in obtaining geographically representative samples of individuals with MPNs in the United States. These approaches may also be effective in other rare diseases.
Highlights
Rare diseases, defined in the United States as conditions affecting fewer than 200,000 people at any given time [1], collectively represent a substantial societal burden and can significantly reduce quality of life for patients and caregivers
The recruitment method yielding the greatest number of respondents was advertisements on Myeloproliferative neoplasms (MPNs)-focused social media (47.6% of respondents), followed by emails (35.1%) and postcards (13.9%) sent through MPN advocacy groups
Living with MPNs survey recruitment statistical, and legal review by the funder to ensure factual accuracy, but the funder did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript with MPNs in the United States
Summary
Rare diseases, defined in the United States as conditions affecting fewer than 200,000 people at any given time [1], collectively represent a substantial societal burden and can significantly reduce quality of life for patients and caregivers. Patient-reported outcomes are critical to understanding the burden faced by individuals with rare diseases; small populations and lack of clinical knowledge and specialized care centers make it difficult to collect widely representative data [1]. Communications from patient advocacy groups and postings or advertisements on social media websites may become valuable avenues for recruiting individuals with rare diseases [6, 7]. Overall survival is reduced among individuals with MPNs compared with the general population [9, 10]. MPNs can negatively affect work ability and productivity, as well as overall quality of life [13, 14]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
